These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 21361292)

  • 21. Discovery of a nortropanol derivative as a potent and orally active GPR119 agonist for type 2 diabetes.
    Xia Y; Chackalamannil S; Greenlee WJ; Jayne C; Neustadt B; Stamford A; Vaccaro H; Xu XL; Baker H; O'Neill K; Woods M; Hawes B; Kowalski T
    Bioorg Med Chem Lett; 2011 Jun; 21(11):3290-6. PubMed ID: 21536438
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Design, synthesis, and biological activity of potent and orally available G protein-coupled receptor 40 agonists.
    Sasaki S; Kitamura S; Negoro N; Suzuki M; Tsujihata Y; Suzuki N; Santou T; Kanzaki N; Harada M; Tanaka Y; Kobayashi M; Tada N; Funami M; Tanaka T; Yamamoto Y; Fukatsu K; Yasuma T; Momose Y
    J Med Chem; 2011 Mar; 54(5):1365-78. PubMed ID: 21319751
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Urotensin-II receptor ligands. From agonist to antagonist activity.
    Grieco P; Carotenuto A; Campiglia P; Marinelli L; Lama T; Patacchini R; Santicioli P; Maggi CA; Rovero P; Novellino E
    J Med Chem; 2005 Nov; 48(23):7290-7. PubMed ID: 16279788
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Parameterization of the GPR119 Receptor Agonist AR231453.
    Hamilton J; Kotsikorou E
    J Comput Chem; 2018 Jan; 39(1):35-41. PubMed ID: 29023843
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inverse agonism or neutral antagonism at G-protein coupled receptors: a medicinal chemistry challenge worth pursuing?
    Greasley PJ; Clapham JC
    Eur J Pharmacol; 2006 Dec; 553(1-3):1-9. PubMed ID: 17081515
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Discovery of 2-(6-{[(6-fluoroquinolin-2-yl)methyl]amino}bicyclo[3.1.0]hex-3-yl)-N-hydroxypyrimidine-5-carboxamide (CHR-3996), a class I selective orally active histone deacetylase inhibitor.
    Moffat D; Patel S; Day F; Belfield A; Donald A; Rowlands M; Wibawa J; Brotherton D; Stimson L; Clark V; Owen J; Bawden L; Box G; Bone E; Mortenson P; Hardcastle A; van Meurs S; Eccles S; Raynaud F; Aherne W
    J Med Chem; 2010 Dec; 53(24):8663-78. PubMed ID: 21080647
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Optimization of 2,4-diaminopyrimidines as GHS-R antagonists: side chain exploration.
    Liu B; Liu M; Xin Z; Zhao H; Serby MD; Kosogof C; Nelson LT; Szczepankiewicz BG; Kaszubska W; Schaefer VG; Falls HD; Lin CW; Collins CA; Sham HL; Liu G
    Bioorg Med Chem Lett; 2006 Apr; 16(7):1864-8. PubMed ID: 16442284
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Optimization of a novel series of potent and orally bioavailable GPR119 agonists.
    Koshizawa T; Morimoto T; Watanabe G; Watanabe T; Yamasaki N; Sawada Y; Fukuda T; Okuda A; Shibuya K; Ohgiya T
    Bioorg Med Chem Lett; 2017 Aug; 27(15):3249-3253. PubMed ID: 28648463
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Discovery of structurally novel, potent and orally efficacious GPR119 agonists.
    Alper P; Azimioara M; Cow C; Mutnick D; Nikulin V; Michellys PY; Wang Z; Reding E; Paliotti M; Li J; Bao D; Zoll J; Kim Y; Zimmerman M; Groessel T; Tuntland T; Joseph SB; McNamara P; Seidel HM; Epple R
    Bioorg Med Chem Lett; 2014 May; 24(10):2383-7. PubMed ID: 24751443
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synthesis and structure-activity relationship of N-(3-azabicyclo[3.1.0]hex-6-ylmethyl)-5-(2-pyridinyl)-1,3-thiazol-2-amines derivatives as NPY Y5 antagonists.
    Biagetti M; Leslie CP; Mazzali A; Seri C; Pizzi DA; Bentley J; Genski T; Di Fabio R; Zonzini L; Caberlotto L
    Bioorg Med Chem Lett; 2010 Aug; 20(16):4741-4. PubMed ID: 20630754
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Stereospecific synthesis of oximes and oxime ethers of 3-azabicycles: A SAR study towards antimicrobial agents.
    Parthiban P; Rathika P; Ramkumar V; Son SM; Jeong YT
    Bioorg Med Chem Lett; 2010 Mar; 20(5):1642-7. PubMed ID: 20138517
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chiral pyrrolo[2,3-d]pyrimidine and pyrimido[4,5-b]indole derivatives: structure-activity relationships of potent, highly stereoselective A1-adenosine receptor antagonists.
    Müller CE; Geis U; Grahner B; Lanzner W; Eger K
    J Med Chem; 1996 Jun; 39(13):2482-91. PubMed ID: 8691445
    [TBL] [Abstract][Full Text] [Related]  

  • 33. From partial to full agonism: identification of a novel 2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole as a full agonist of the human GPR119 receptor.
    Futatsugi K; Mascitti V; Guimarães CR; Morishita N; Cai C; DeNinno MP; Gao H; Hamilton MD; Hank R; Harris AR; Kung DW; Lavergne SY; Lefker BA; Lopaze MG; McClure KF; Munchhof MJ; Preville C; Robinson RP; Wright SW; Bonin PD; Cornelius P; Chen Y; Kalgutkar AS
    Bioorg Med Chem Lett; 2013 Jan; 23(1):194-7. PubMed ID: 23177788
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Design, synthesis, stereochemistry and antioxidant properties of various 7-alkylated 2,4-diaryl-3-azabicyclo[3.3.1]nonan-9-ones.
    Park DH; Venkatesan J; Kim SK; Parthiban P
    Bioorg Med Chem Lett; 2012 Sep; 22(18):6004-9. PubMed ID: 22884407
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A concise synthesis of 1,4-dihydro-[1,4]diazepine-5,7-dione, a novel 7-TM receptor ligand core structure with melanocortin receptor agonist activity.
    Szewczyk JR; Laudeman CP; Sammond DM; Villeneuve M; Minick DJ; Grizzle MK; Daniels AJ; Andrews JL; Ignar DM
    Bioorg Med Chem; 2010 Mar; 18(5):1822-33. PubMed ID: 20172734
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Functional selectivity of GPCR ligand stereoisomers: new pharmacological opportunities.
    Seifert R; Dove S
    Mol Pharmacol; 2009 Jan; 75(1):13-8. PubMed ID: 19001067
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synthesis and biological evaluation of pyrimidine derivatives with diverse azabicyclic ether/amine as novel GPR119 agonist.
    Yang Z; Fang Y; Park H
    Bioorg Med Chem Lett; 2017 Jun; 27(11):2515-2519. PubMed ID: 28408218
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Exploration of the amine terminus in a novel series of 1,2,4-triazolo-3-yl-azabicyclo[3.1.0]hexanes as selective dopamine D3 receptor antagonists.
    Micheli F; Arista L; Bertani B; Braggio S; Capelli AM; Cremonesi S; Di-Fabio R; Gelardi G; Gentile G; Marchioro C; Pasquarello A; Provera S; Tedesco G; Tarsi L; Terreni S; Worby A; Heidbreder C
    J Med Chem; 2010 Oct; 53(19):7129-39. PubMed ID: 20839775
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ligand-specific conformation determines agonist activation and antagonist blockade in purified human thromboxane A2 receptor.
    Ruan KH; Cervantes V; Wu J
    Biochemistry; 2009 Apr; 48(14):3157-65. PubMed ID: 19170518
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Design of potent and selective GPR119 agonists for type II diabetes.
    Szewczyk JW; Acton J; Adams AD; Chicchi G; Freeman S; Howard AD; Huang Y; Li C; Meinke PT; Mosely R; Murphy E; Samuel R; Santini C; Yang M; Zhang Y; Zhao K; Wood HB
    Bioorg Med Chem Lett; 2011 May; 21(9):2665-9. PubMed ID: 21273063
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.